A study has developed an innovative method that overcomes the limitations of traditional additive manufacturing (3D printing), significantly simplifying and accelerating the production of ...

CAMBRIDGE, England & BAD HOMBURG, Germany--(BUSINESS WIRE)--Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that ...

Additive manufacturing of cellular lattice structures has emerged as a transformative approach to fabricating lightweight, high-performance materials with precise control over internal architecture.

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for non-responsive or relapsing hematological malignancies, providing an intensive, personalized form of immunotherapy. It ...

Cellular Origins, a TTP company, acquired the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge while CEO of SOTIO Biotech US. The ACTIA Platform complements ...

A study led by the School of Engineering of the Hong Kong University of Science and Technology (HKUST) has developed an innovative method that overcomes the limitations of traditional additive ...